| Title |
A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, October 2017
|
| DOI | 10.2147/tcrm.s144681 |
| Pubmed ID | |
| Authors |
Chao Liu, Ling Ding, Ye-han Zhu, Cheng Chen |
| Abstract |
Nosocomial infections by Klebsiella pneumoniae, especially those due to multidrug-resistant strains, are being increasingly detected. In this report, we present the case of a 63-year-old man with lung squamous carcinoma who received nivolumab therapy due to failure of first-line chemotherapy. This report also demonstrates an association of nivolumab therapy and neutropenia, and supports the use of a combination of tigecycline and meropenem in managing hospitalization-acquired pneumonia caused by multidrug-resistant K. pneumoniae. It also implicates that a further evaluation is required in lung cancer patients with a suspected metastatic or recurrent carcinoma, and an antibiotic therapy is valuable in ruling out a potential lung infection since a risk of hospitalization-acquired pneumonia may exist. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 25% |
| Student > Master | 3 | 13% |
| Student > Doctoral Student | 2 | 8% |
| Other | 2 | 8% |
| Student > Postgraduate | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 10 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
| Unknown | 12 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2017.
All research outputs
#20,663,600
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,070
of 1,323 outputs
Outputs of similar age
#256,968
of 331,218 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#26
of 31 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,218 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.